In this video interview, Umesh Chaudhari, executive medical director and global program head of the C5 programs at Regeneron, ...

Results from the Phase III STRIDE-13 trial (NCT06177912) showed that Merck’s Capvaxive (Pneumococcal 21-valent Conjugate Vaccine) demonstrated robust immune responses in children and adolescents aged ...

In this Q&A, Randa Wahid of Indero, and Lyn Mursalo, a freelance clinical research professional, share how sponsors and CROs ...

Five-year results from the Phase III EMPOWER-Lung 3 trial show Libtayo combined with chemotherapy achieved a 19.4% overall ...

Results from the Phase III FLAUR2 trial (NCT04035486) showed that Tagrisso combined with pemetrexed and platinum-based ...

The FDA-approved therapy is now included in National Comprehensive Cancer Network clinical guidelines as a treatment option ...

The FDA has granted Fast Track Designation to Sanofi’s SAR402663, an investigational one-time intravitreal gene therapy for ...

In this video interview, Adrianne Rivard, senior community development manager at myTomorrows, explains why compliance with ...

Results from a Phase II trial (NCT06449209) showed that BioNTech’s and Bristol Myers Squibb’s pumitamig in combination with ...

Results from the Phase II EPCORE NHL-6 trial showed that Genmab’s and AbbVie’s Epkinly (epcoritamab) demonstrated encouraging ...

Results from the Phase III HARMONi trial (NCT06396065) showed that Summit Therapeutics’ ivonescimab demonstrated a positive ...

In this episode of the Applied Clinical Trials Brief, Shipra Patel, global therapeutic area section head for endocrinology ...